Overview


According to FutureWise analysis, the market for Insulin Lispro is expected to grow with a CAGR of 4.40% over the forecast period 2024-2032, and reach a market value of US$ 5.77 Billion by 2031.  

Insulin lispro is a rapid-acting synthetic form of human insulin designed to mimic the natural insulin produced by the pancreas closely. It is utilized to manage diabetes mellitus, a persistent condition marked by elevated blood sugar levels resulting from insufficient insulin production or an inadequate insulin response. Insulin lispro shows the onset of action approximately 15 minutes after administration. This rapid onset aligns with the physiological insulin response triggered by meals, making it particularly effective in controlling post-meal blood sugar spikes. 

The formulation of insulin lispro has been engineered to enhance its absorption and availability in the bloodstream. This is achieved by modifying the structure of regular human insulin, allowing for faster absorption after subcutaneous injection. Due to these modifications, insulin lispro is often favored over regular insulin in managing postprandial glucose levels. Administered via subcutaneous injection, insulin lispro is typically given right before or immediately after meals, effectively regulating blood sugar levels in response to food consumption. It can also be used in insulin pumps, providing a continuous supply of insulin throughout the day.

FutureWise Market Research has published a report that provides an insightful analysis of Insulin Lispro Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Insulin Lispro Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Johnson & Johnson Services, Inc.
  • Biocon Limited
  • Mylan N.V.
  • Boehringer Ingelheim International GmbH
  • Wockhardt Ltd.
  • Lupin Pharmaceuticals, Inc.
  • Bioton S.A.
  • Ypsomed AG.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The global increase in diabetes cases, type 1 and type 2, is a significant driver for the Insulin Lispro market. As more individuals require insulin therapy, the demand for rapid-acting insulins like Insulin Lispro is expected to grow. Ongoing research and development efforts in diabetes management have created more advanced and efficient insulin formulations. This includes rapid-acting insulins like Insulin Lispro, which offer improved glycaemic control. Patients often prefer rapid-acting insulins due to their quicker onset of action, providing better post-meal blood sugar control and flexibility in meal timing. Adequate insurance coverage and reimbursement policies for diabetes management, including insulin therapies, can drive market growth, making these treatments more accessible to patients.

However, the market for insulins is competitive, with the availability of biosimilar insulins offering similar efficacy at potentially lower costs. This competition could impact the market share of branded Insulin Lispro.  Stringent regulatory requirements for approval and market entry can challenge insulin manufacturers. Meeting these standards is critical but can be time-consuming and resource-intensive.  Access to advanced insulin therapies may be limited in certain developing regions due to cost, infrastructure, and healthcare policies. This could hinder market expansion in these areas.

By Type of Insulin Lispro

  • Rapid-acting Insulin Lispro
  • Long-acting Insulin Lispro

By Delivery Method

  • Insulin Pens
  • Insulin Syringes
  • Insulin Pumps

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

By Age Group

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Brand

  • Humalog (Eli Lilly and Company)
  • Admelog (Sanofi)
  • Other Brands

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the high prevalence of diabetes and a well-established healthcare system. Conversely, the European region is poised for substantial expansion in the forecast period due to a well-developed healthcare infrastructure and a high prevalence of diabetes. 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Insulin Lispro Market By Type of Insulin Lispro, By Delivery Method, By Indication, By Age Group, By Distribution Channel, By Brand, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2. Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Insulin Lispro Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Insulin Lispro Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Insulin Lispro Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Insulin Lispro Market, By Type of Insulin Lispro Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Rapid-acting Insulin Lispro
        2. Long-acting Insulin Lispro

  • 8.  Insulin Lispro Market, By Delivery Method Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Insulin Pens
        2. Insulin Syringes
        3. Insulin Pumps

  • 9.  Insulin Lispro Market, By Indication Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Type 1 Diabetes
        2. Type 2 Diabetes
        3. Gestational Diabetes
        4. Others

  • 10.  Insulin Lispro Market, By Age Group Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Pediatric Patients
        2. Adult Patients
        3. Geriatric Patients

  • 11.  Insulin Lispro Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 12.  Insulin Lispro Market, By Brand Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Humalog (Eli Lilly and Company)
        2. Admelog (Sanofi)
        3. Other Brands

  • 13.  North America Insulin Lispro Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 14.  Latin America Insulin Lispro Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 15.  Europe Insulin Lispro Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 16.  Asia Pacific Insulin Lispro Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 17.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 18.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 19.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Eli Lilly and Company
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Sanofi
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Novo Nordisk A/S
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Merck & Co., Inc.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Pfizer Inc.
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. F. Hoffmann-La Roche Ltd.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. AstraZeneca PLC
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Johnson & Johnson Services, Inc.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. Biocon Limited
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Mylan N.V.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. Boehringer Ingelheim International GmbH
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. Wockhardt Ltd.
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Lupin Pharmaceuticals, Inc.
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Bioton S.A.
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Ypsomed AG.
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview

  • 20.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
             administrations
        5. The overall economic slowdown of the developing and developed nations

  • 21.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients